focus -WSS

focus

author：knowledge 2025-08-19 12:15:05 - browse：71332

The home health industry lobbying group is suing Medicare over new payment cuts. But profits in the sector remain near all-time highs. Business Insider/AP

The National Association of Home Care and Hospice sued the Biden administration to halt the government’s recent proposed rule that would cut Medicare payments to home health agencies by 2.2% in 2024.

Since 2020, Medicare has updated its system for how it pays for home health, in particular by basing payments less on how much therapy someone is getting at home. By law, the new system can’t cost more or less than it otherwise would have, but Medicare reinforced this year that it had “paid more under the new system than it would have under the old system” — and thus continued cuts to home health for next year.

Newsletters

Sign up for STAT Health Care Inc.

Following the flow of money through the health care industry.

Please enter a valid email address. Privacy Policy

NAHC, the home health industry’s lobbying group, said in its lawsuit that Medicare has been violating the requirement to keep things “budget-neutral” and threatens to put home health operators out of business. But one thing NAHC failed to mention: Profits in the home health industry remain near all-time highs.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Medicare details structure of new drug price negotiation program
Next article： CZI to create biohub to build anti

WSS

STAT Summit: Meghan O’Rourke on making chronic illness visible

STAT Summit: The economic case for universal basic health care

Cassava Sciences’ Alzheimer’s clinical trials should be halted

Harvard's Jason Buenrostro wins MacArthur grant for genetics work

STAT Summit: How researchers deal with rejection

UnitedHealth, Optum discontinue NaviHealth name

explore

focus

Sign up for STAT Health Care Inc.

focus

BioMarin wins approval for gene therapy to treat hemophilia A

The future of Biogen: Pragmatism, ‘moonshots,’ and no Twinkies

Novavax promises a turnaround & Lilly roils the obesity market

STAT Summit: Meghan O’Rourke on making chronic illness visible

Sports medicine is finally prioritizing gender equality

Readout Newsletter: AstraZeneca's CEO, Roivant's $5 billion deal

Medical records are filled with copy

UnitedHealth, Optum discontinue NaviHealth name

Tori Bowie and the unacceptable rates of Black maternal death

Questions loom on AstraZeneca cancer drug as safety concerns ebb

knowledge

Health tech investors get more selective as pandemic boom fades

CZI to create biohub to build anti

Roche acquires Telavant from Roivant, adding experimental IBD treatment

Why a market frenzy over new weight loss drugs defies logic

Roche acquires Telavant from Roivant, adding experimental IBD treatment

Results on Novartis prostate cancer therapy could expand its use

focus

entertainment

entertainment

focus